
Akerman announced the growth of its Washington, D.C. office with the addition of Corporate Partner Austin Ownbey. Ownbey joins Akerman as a specialist in antitrust counseling and Hart-Scott-Rodino (HSR) filings, bringing experience in competition and antitrust issues to the firm.
An accomplished antitrust regulatory practitioner, Ownbey provides counsel on a wide range of competition and antitrust matters, including merger reviews and enforcement issues before competition agencies in the United States and globally. His expertise spans multiple industries such as healthcare, pharmaceuticals, private equity, venture capital, technology, and energy.
Throughout his career, Ownbey has represented clients before key regulatory bodies including the U.S. Department of Justice, Antitrust Division (DOJ), the Federal Trade Commission (FTC), state attorneys general, and foreign antitrust enforcement agencies. He is particularly adept at guiding clients through the HSR merger review process and other merger control filings.
Ownbey’s background includes experience as a staff attorney at the FTC, where he handled merger and conduct investigations and consumer protection litigation. His practice also extends to advising cannabis clients on licensing processes and compliance with regulatory requirements across the United States.
“Austin brings new depth and breadth to our national corporate practice, and we are thrilled he is joining our partnership,” said Corporate Practice Group Co-Chair Jonathan Awner.
Source: Akerman
Featured News
Judge Orders Apple to Address Fortnite App Block or Face Court Hearing
May 19, 2025 by
CPI
EU Civil Society Groups and Labor Unions Raise Alarm Over Proposed Changes to GDPR
May 19, 2025 by
CPI
EU Antitrust Regulators Push Back Deadline on UniCredit’s Takeover Bid for Banco BPM
May 19, 2025 by
CPI
Intel Challenges €376 Million EU Fine in Ongoing Antitrust Dispute
May 19, 2025 by
CPI
Red Bull Challenges EU Commission Over Lengthy Antitrust Inspection
May 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas